Launching this first-in-human trial marks an important milestone for ViroMissile and our mission to reshape cancer immunotherapy with selective viruses that target tumors while sparing healthy tissue, ...
The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...
News-Medical.Net on MSN
External signals control oncolytic bacteria for precise cancer therapy delivery
Engineered oncolytic bacteria have emerged as a promising therapeutic platform for precision cancer treatment, offering tumor ...
VV169 saw complete clearance of disseminated myeloma tumors within 28 daysAnother dataset highlights Vyriad’s work in improved vector retargeting strategies in a comparative study of three methods for ...
Strasbourg (France), December 17, 2025, 17:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...
ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the appointment of Mark Bertagnolli as Chief Operating ...
A new groundbreaking study has recently identified the link between the long-standing mystery in autoimmune disease: Epstein-Barr Virus (EBV) and how it contributes towards the development of systemic ...
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results